Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy

Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)

DRUG

Paclitaxel + Carboplatin + Radiotherapy

Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week

Trial Locations (5)

110041

RECRUITING

Liaoning Cancer Hospital and Institute, Shenyang

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

300202

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

515041

RECRUITING

Cancer Hospital of Shantou University Medical College, Shantou

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER